Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Study identifies gene variants associated with histological features of NAFLD

More patients could be diagnosed earlier with non-alcoholic fatty liver disease after a cohort study presented at the International Liver Congress 2013 identified variants within four genes significantly associated with the histological features of the disease.

24 Apr 2013

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen R&D Ireland today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Medivir AB today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients.

23 Apr 2013

Unavoidable damage to heart and lungs can be limited by using CVD drug

Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.

23 Apr 2013

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco in combination with another potential CF therapy, VX-661.

23 Apr 2013

Selenium research performed by Dr. Joel Wallach continues to be at the forefront of health and prevention

Youngevity® Essential Life Sciences, a wholly-owned subsidiary of AL International, Inc., announces that the research of Youngevity® founder, Dr. Joel D. Wallach, BS, DVM, ND, on Selenium continues to be at the forefront of health and prevention with the recent U.S. Food and Drug Administration (FDA) proposed rule requiring the addition of selenium to the list of required nutrients for infant formula products.

22 Apr 2013

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Vertex Pharmaceuticals Incorporated today announced data from a Phase 2 study of VX-661 and ivacaftor that showed statistically significant improvements in lung function among adults with cystic fibrosis (CF) who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, known as F508del.

22 Apr 2013

Study identifies seven new genetic regions associated with pulmonary fibrosis

A new genome-wide association study of more than 6,000 people has identified seven new genetic regions associated with pulmonary fibrosis. In findings published online in Nature Genetics on April 14, 2013, researchers at National Jewish Health, the University of Colorado and several other institutions found a number of genes associated with host defense, cell-cell adhesion and DNA repair, which provide clues to possible mechanisms underlying this currently untreatable disease.

20 Apr 2013

EKG could predict cardiovascular illness

A common test that records the heart's electrical activity could predict potentially serious cardiovascular illness, according to a UC San Francisco-led study.

17 Apr 2013

Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis, a rare and devastating lung disease, found multiple genetic associations with the disease, including one gene variant that was linked to an increase in the risk of death.

17 Apr 2013

Study finds genetic variation is associated with pulmonary fibrosis risk

A newly published study of patients with pulmonary fibrosis has discovered multiple genetic variations that should help with future efforts to treat the disease.

16 Apr 2013

New study examines role of mast cells in development of idiopathic pulmonary fibrosis

Pulmonary fibrosis is a chronic, deadly disease that affects five million people worldwide. It is irreversible, its cause is poorly understood, and it has a median survival of only about 3 years.

15 Apr 2013

Protein EPAC2 plays major role in development of type 2 diabetes

A team of researchers at the Johns Hopkins Children's Center has found that a protein long believed to have a minor role in type 2 diabetes is, in fact, a central player in the development of the condition that affects nearly 26 million people in the United States alone and counts as one of the leading causes of heart disease, stroke and kidney, eye and nerve damage.

12 Apr 2013

Computational simulations can help understand, treat cardiac rhythm disorders

Computational models of the human heart can be very useful in studying not just the basic mechanisms of heart function, but also to analyze the heart in a diseased state, and come up with methods for diagnosis and therapy.

11 Apr 2013

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis.

10 Apr 2013

Physicians uncertain about hospitalization for PID treatment

A Johns Hopkins Children's Center survey of 102 clinicians who treat teenage girls with pelvic inflammatory disease has found that official guidelines designed to inform decisions about hospitalization versus outpatient care leave some clinicians scratching their heads.

10 Apr 2013

Johns Hopkins researchers find how gout-linked genetic mutation contributes to disease

Johns Hopkins scientists have found out how a gout-linked genetic mutation contributes to the disease: by causing a breakdown in a cellular pump that clears an acidic waste product from the bloodstream.

9 Apr 2013

Liver transplants worth risk for people who have genetic liver conditions, study finds

Patients faced with the diagnosis of a life-threatening liver disease have to consider the seriousness of having a liver transplant, which can be a definitive cure for many acquired and genetic liver diseases.

6 Apr 2013

Vertex to conduct two Phase 2 studies of VX-135 in combination with daclatasvir

Vertex Pharmaceuticals Incorporated today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertex's nucleotide analogue hepatitis C virus polymerase inhibitor VX-135 and Bristol-Myers Squibb's NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C.

6 Apr 2013

Fibrosis News and Research

Further Reading

Study identifies gene variants associated with histological features of NAFLD

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Unavoidable damage to heart and lungs can be limited by using CVD drug

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

Selenium research performed by Dr. Joel Wallach continues to be at the forefront of health and prevention

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Study identifies seven new genetic regions associated with pulmonary fibrosis

EKG could predict cardiovascular illness

Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

Study finds genetic variation is associated with pulmonary fibrosis risk

New study examines role of mast cells in development of idiopathic pulmonary fibrosis

Protein EPAC2 plays major role in development of type 2 diabetes

Computational simulations can help understand, treat cardiac rhythm disorders

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Physicians uncertain about hospitalization for PID treatment

Johns Hopkins researchers find how gout-linked genetic mutation contributes to disease

Liver transplants worth risk for people who have genetic liver conditions, study finds

Vertex to conduct two Phase 2 studies of VX-135 in combination with daclatasvir

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News